These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 2885346)

  • 21. Pimozide augmentation for the treatment of schizophrenic patients who are partial responders to clozapine.
    Friedman J; Ault K; Powchik P
    Biol Psychiatry; 1997 Sep; 42(6):522-3. PubMed ID: 9285089
    [No Abstract]   [Full Text] [Related]  

  • 22. A meta-analysis and critical review of the effects of conventional neuroleptic treatment on cognition in schizophrenia: opening a closed book.
    Mishara AL; Goldberg TE
    Biol Psychiatry; 2004 May; 55(10):1013-22. PubMed ID: 15121486
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The relationship of the brief psychiatric rating scale to neuropsychological deficits in phenothiazine-treated schizophrenics.
    Golden CJ; Carpenter B; Wilkening G; Ruedrich S; Chu CC; Graber B
    Psychopharmacol Bull; 1983; 19(3):513-7. PubMed ID: 6138799
    [No Abstract]   [Full Text] [Related]  

  • 24. Reevaluation of chronically ill psychiatric patients.
    J Clin Psychiatry; 1988 Oct; 49(10):413-4. PubMed ID: 2902072
    [No Abstract]   [Full Text] [Related]  

  • 25. Electroencephalography in schizophrenic patients: comparison between neuroleptic-naive state and after treatment.
    Nagase Y; Okubo Y; Toru M
    Biol Psychiatry; 1996 Sep; 40(6):452-6. PubMed ID: 8879464
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Systematic dosage reduction in treatment-resistant schizophrenic patients.
    Van Putten T; Marshall BD; Liberman R; Mintz J; Kuehnel TG; Bowen L; Aravagiri M; Marder SR
    Psychopharmacol Bull; 1993; 29(2):315-20. PubMed ID: 7904763
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Neuroleptic-resistant schizophrenia treated with clozapine and ECT.
    Benatov R; Sirota P; Megged S
    Convuls Ther; 1996 Jun; 12(2):117-21. PubMed ID: 8744173
    [TBL] [Abstract][Full Text] [Related]  

  • 28. ICI 204,636: a new atypical antipsychotic drug.
    Hirsch SR; Link CG; Goldstein JM; Arvanitis LA
    Br J Psychiatry Suppl; 1996 May; (29):45-56. PubMed ID: 8733823
    [No Abstract]   [Full Text] [Related]  

  • 29. Actometry and Barnes Akathisia Rating Scale in neuroleptic-induced akathisia.
    Janno S; Holi MM; Tuisku K; Wahlbeck K
    Eur Neuropsychopharmacol; 2005 Jan; 15(1):39-41. PubMed ID: 15572272
    [TBL] [Abstract][Full Text] [Related]  

  • 30. High-dose versus low-dose strategies in the treatment of schizophrenia.
    Kane JM; Rifkin A; Woerner M; Reardon G; Kreisman D; Blumenthal R; Borenstein M
    Psychopharmacol Bull; 1985; 21(3):533-7. PubMed ID: 2863848
    [No Abstract]   [Full Text] [Related]  

  • 31. Seroquel and cognitive improvement in patients with schizophrenia.
    Stip E; Lussier I; Babai M; Fabian JL; Link C
    Biol Psychiatry; 1996 Sep; 40(5):434-5. PubMed ID: 8874852
    [No Abstract]   [Full Text] [Related]  

  • 32. Clinical predictors of therapeutic response to clozapine in a sample of Turkish patients with treatment-resistant schizophrenia.
    Semiz UB; Cetin M; Basoglu C; Ebrinc S; Uzun O; Herken H; Balibey H; Algul A; Ates A
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 Aug; 31(6):1330-6. PubMed ID: 17618026
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Scales for the assessment of neuroleptic response in schizophrenic children: specific measures derived from the CPRS.
    Spencer EK; Alpert M; Pouget ER
    Psychopharmacol Bull; 1994; 30(2):199-202. PubMed ID: 7831455
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Weight gain and clozapine].
    Jalenques I; Tauveron I; Albuisson E; Audy V
    Encephale; 1996 Oct; 22 Spec No 3():77-9. PubMed ID: 8954282
    [No Abstract]   [Full Text] [Related]  

  • 35. Quetiapine for elderly non-responsive schizophrenia patients.
    Mazeh D; Paleacu D; Barak Y
    Psychiatry Res; 2008 Jan; 157(1-3):265-7. PubMed ID: 17928067
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Childhood stressors, parental expectation, and the development of schizophrenia.
    Mirsky AF; Ingraham LJ; Lowing PA
    Prog Exp Pers Psychopathol Res; 1992; 15():110-30. PubMed ID: 1364178
    [No Abstract]   [Full Text] [Related]  

  • 37. Subjective response and attitudes toward antipsychotic drug therapy during the initial treatment period: a prospective follow-up study in patients with schizophrenia.
    Hofer A; Rettenbacher MA; Edlinger M; Kemmler G; Widschwendter CG; Fleischhacker WW
    Acta Psychiatr Scand; 2007 Nov; 116(5):354-61. PubMed ID: 17868428
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Frontal lobe tasks, antipsychotic medication, and schizophrenia syndromes.
    Himelhoch S; Taylor SF; Goldman RS; Tandon R
    Biol Psychiatry; 1996 Feb; 39(3):227-9. PubMed ID: 8837987
    [No Abstract]   [Full Text] [Related]  

  • 39. Early neuroleptic intervention in schizophrenia: are prodromal symptoms valid predictors of relapse?
    Gaebel W; Frick U; Köpcke W; Linden M; Müller P; Müller-Spahn F; Pietzcker A; Tegeler J
    Br J Psychiatry Suppl; 1993 Sep; (21):8-12. PubMed ID: 8105814
    [TBL] [Abstract][Full Text] [Related]  

  • 40. An early phase II clinical trial of remoxipride in schizophrenia with measurement of plasma neuroleptic activity.
    Chouinard G; Turnier L
    Psychopharmacol Bull; 1986; 22(1):267-71. PubMed ID: 2873615
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.